I seriously doubt that so we respectfully disagree. It's doubtful that AVXL would participate in any such rally when its lead drug is perceived to have failed in both a AD and a Rett trial. Unless Missling can file an MAA in Europe and have it advance toward regulatory approval, it will be left with 2-73 in a small Phase II schizophrenia trial and Rett in total limbo.